Weekly carboplatin + paclitaxel concurrent with definitive RT (esophageal)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CARBOPLATIN` `DRUG-PACLITAXEL`

ID	`REG-CARBO-PACLI-CONCURRENT-RT-ESOPH`
Type	Regimen
Status	reviewed 2026-05-08 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-ESOPHAGEAL-2024` `SRC-NCCN-ESOPHAGEAL-2025` `SRC-RTOG-8501-HERSKOVIC-1992`

Notes

Definitive concurrent chemoradiation chemo backbone for unresectable (T4b), M0, medically inoperable, or surgery-declining esophageal squamous-cell carcinoma. Paired with RC-DEFINITIVE-ESOPH-SCC (50.4 Gy / 28 fx) per NCCN ESOPH-F preferred definitive CRT regimen. Evolved from RTOG 85-01 (cisplatin + 5-FU + 50 Gy) backbone with improved tolerability profile; weekly carbo+pacli now NCCN/ESMO preferred chemo backbone for definitive CRT in SCC. Distinct from REG-CARBOPLATIN-PACLITAXEL-WEEKLY (CROSS neoadjuvant 5 cycles + 41.4 Gy / 23 fx) — same drugs/doses but different RT pairing and cycle count.

Used By

Algorithms

ALGO-ESOPH-DEFINITIVE-1L - ALGO-ESOPH-DEFINITIVE-1L

Indication

IND-ESOPH-DEFINITIVE-CRT-SCC - IND-ESOPH-DEFINITIVE-CRT-SCC

Radiation Courses

RC-DEFINITIVE-ESOPH-SCC - Definitive concurrent chemoradiation for unresectable esophageal SCC